The pharmaceutical industry is facing pressure from the current administration to lower prices and increase access to medications. Despite this, three major companies – Pfizer, Novo Nordisk, and Eli Lilly – are identified as undervalued. Pfizer is trading at $25.60 with an intrinsic value of over $80. Novo Nordisk is trading at $62.53, with an intrinsic value of $82.64, and also has a first-to-market oral pill for weight loss. Eli Lilly is trading near its 52-week high at $1,068.97, with an intrinsic value of $1,600, and has shown exceptional performance. All three are rated as buy, with Eli Lilly being the top pick for 2026.